Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: The prostate 81.2021, 16, S. 1294-1302, doi:10.1002/pros.24224
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2021
- Urheber
-
Wenzel, Mike
Würnschimmel, Christoph
Chierigo, Francesco
Tian, Zhe
Shariat, Shahrokh F.
Terrone, Carlo
Saad, Fred
Tilki, Derya
Graefen, Markus
Banek, Séverine
Kluth, Luis
Mandel, Philipp
Chun, Felix
Karakiewicz, Pierre I.
- URN
-
urn:nbn:de:hebis:30:3-644110
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wenzel, Mike
- Würnschimmel, Christoph
- Chierigo, Francesco
- Tian, Zhe
- Shariat, Shahrokh F.
- Terrone, Carlo
- Saad, Fred
- Tilki, Derya
- Graefen, Markus
- Banek, Séverine
- Kluth, Luis
- Mandel, Philipp
- Chun, Felix
- Karakiewicz, Pierre I.
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2021
Ähnliche Objekte (12)
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
The effect of primary urological cancers on survival in men with secondary prostate cancer
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy
The effect of primary urological cancers on survival in men with secondary prostate cancer
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
The effect of primary urological cancers on survival in men with secondary prostate cancer
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy
The effect of primary urological cancers on survival in men with secondary prostate cancer
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
The effect of primary urological cancers on survival in men with secondary prostate cancer
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy
The effect of primary urological cancers on survival in men with secondary prostate cancer
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis